<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04842344</url>
  </required_header>
  <id_info>
    <org_study_id>2020-KE-492</org_study_id>
    <nct_id>NCT04842344</nct_id>
  </id_info>
  <brief_title>ECCO2R in the Treatment of Acute Exacerbation of COPD With Severe Hypercapnia</brief_title>
  <official_title>A Prospective Randomized Controlled Trial of Extracorporeal Carbon Dioxide Removal (ECCO2R) in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease With Severe Hypercapnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Li Xuyan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with moderate to severe acute exacerbation of chronic obstructive pulmonary disease&#xD;
      are often complicated with hypercapnia and respiratory failure, so they need to be admitted&#xD;
      to ICU for monitoring and respiratory support treatment. Noninvasive ventilation has become&#xD;
      the first-line respiratory support for the treatment of AECOPD with hypercapnia and&#xD;
      respiratory failure. However, 26-54% of AECOPD patients with hypercapnia and respiratory&#xD;
      failure eventually fail to receive noninvasive ventilation and need endotracheal intubation&#xD;
      and invasive ventilation to maintain effective gas exchange. For these patients, the&#xD;
      in-hospital survival rate is only 31-76%, and the prognosis is poor. In AECOPD patients with&#xD;
      high risk of noninvasive ventilation failure and expected need of intubation, timely giving&#xD;
      other ways of respiratory support to reduce blood CO2 may avoid patients receiving tracheal&#xD;
      intubation and invasive ventilation, thus avoiding related complications and adverse&#xD;
      prognosis. As a new type of respiratory support technology, ECCO2R is worthy of attention in&#xD;
      monitoring and evaluation of support effect in AECOPD patients with respiratory failure. It&#xD;
      is urgent that ECCO2R can effectively alleviate respiratory failure, avoid complications&#xD;
      related to tracheal intubation, improve quality of life and reduce mortality.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Demand rate of endotracheal intubation</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Actual rate of endotracheal intubation</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of ICU stay</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospital stay</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Lung Diseases, Obstructive</condition>
  <arm_group>
    <arm_group_label>Noninvasive ventilation and ECCO2R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Noninvasive ventilation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ECCO2R</intervention_name>
    <description>extracorporeal carbon dioxide removal</description>
    <arm_group_label>Noninvasive ventilation and ECCO2R</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AECOPD patients.&#xD;
&#xD;
          -  The patients with hypercapnia respiratory failure were admitted to ICU and needed&#xD;
             noninvasive ventilation.&#xD;
&#xD;
          -  The results of blood gas analysis showed pH &lt;7.30, PaCO2&gt; 50 mmHg.&#xD;
&#xD;
          -  There were high risk factors for failure of noninvasive ventilation: after receiving&#xD;
             continuous 2 hours of noninvasive ventilation, the arterial blood pressure showed the&#xD;
             pH value was ≤ 7.30, while PaCO2 was 20% higher than the baseline value, and any one&#xD;
             or more of the following conditions were combined: respiratory rate ≥ 30 times / min,&#xD;
             assisted respiratory muscle breathing; contradictory breathing.&#xD;
&#xD;
          -  Informed consents were sighed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The mean arterial pressure was less than 60 mmHg after volume and vasoactive drug&#xD;
             treatment.&#xD;
&#xD;
          -  There were anticoagulant contraindications.&#xD;
&#xD;
          -  Weight over 120kg.&#xD;
&#xD;
          -  Patients with malignant tumor or other complications, the expected survival time was&#xD;
             less than 30 days.&#xD;
&#xD;
          -  It could not cooperate with noninvasive ventilation or has contraindication of&#xD;
             noninvasive ventilation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bing Sun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chao Yang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuyan Li, MD</last_name>
    <phone>86013581851048</phone>
    <email>araklee@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bing Sun, MD</last_name>
    <phone>86013911151075</phone>
    <email>ricusunbing@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Institute of Respiratory Medicine, Beijing Chao-yang Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuyan Li</last_name>
      <phone>+8613581851048</phone>
      <email>araklee@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>April 10, 2021</last_update_submitted>
  <last_update_submitted_qc>April 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Li Xuyan</investigator_full_name>
    <investigator_title>Sponsor Investigator</investigator_title>
  </responsible_party>
  <keyword>Acute exacerbation of chronic obstructive pulmonary disease</keyword>
  <keyword>extracorporeal carbon dioxide removal</keyword>
  <keyword>Hypercapnia respiratory failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Hypercapnia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

